Table 2.
Detailed treatment results during the pre-sorafenib, sorafenib, and post-sorafenib stages.
| Variables | Pre-Sorafenib Stage | Sorafenib Stage | Post-Sorafenib Stage |
|---|---|---|---|
| Intervals (years) | 2.8 ± 2.5 | 1.3 ± 1.1 | 0.7 ± 0.5 |
| Treatment during each stage | |||
| Surgical resection (none/1/≥2 [times]) | 28/30/3 | 61/0/0 | 61/0/0 |
| RFA (none/1/2/3/≥4 [times]) | 38/4/11/3/5 | 58/2/0/1 | 51/9/0/0 |
| TACE (none/1/2/3/4/≥5 [times]) | 8/11/9/7/8/18 | 23/14/9/2/13 | 48/6/3/0/1/3 |
| Radiation therapy (none/1/≥2 [times]) | 45/13/3 | 53/6/2 | 51/9/1 |
| Other molecular target drugs (no/yes) | 61/0 | 61/0 | 56/5 * |
* Lenvatinib was used for 4 cases and regorafenib for 1 case. RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization.